PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Alpha-lipoic acid — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Alpha-lipoic acid (thioctic acid) is an antioxidant; in the 3-week ALADIN trial in 328 people with type 2 diabetes and painful neuropathy, daily intravenous infusions of 600 or 1,200 mg reduced foot symptom scores more than placebo. · pmid:8786016

A meta-analysis of four placebo-controlled trials (1,258 patients) found that three weeks of daily intravenous alpha-lipoic acid reduced neuropathic symptoms 24.1% more than placebo. · pmid:14984445

Identity

PubChem CID 864: alpha Lipoic acid, C8H14O2S2, 206.3 g/mol. · pubchem:864

CAS registry number 1077-28-7. · pubchem:864

IUPAC name: 5-(dithiolan-3-yl)pentanoic acid. · pubchem:864

Where the evidence actually sits

Established50%
Emerging50%

Proportion of the 2 claims about Alpha-lipoic acid standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). (1995) · emergingTreatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. (2004) · established19952004

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Alpha-lipoic acid yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. · pmid 14984445 · 2004
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). · pmid 8786016 · 1995
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.